Natalizumab High Titer Immunogenicity and Safety

Summary

The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with relapsing forms of multiple sclerosis (MS). The secondary objective of this study was to evaluate the safety of natalizumab high titer.

Timeline

Start

2006-10

Primary completion

2007-10

Completion

2007-12

Drugs

Indications